Drug Profile
HuMax IL8 - Bristol-Myers Squibb/Genmab
Alternative Names: anti-IL8 mAb - Bristol-Myers Squibb/Genmab; BMS-986253; HuMax-IL8; HuMax-Inflam; HuMax®-IL8; MDX 018Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genmab; Medarex
- Developer Bristol-Myers Squibb; Columbia University; Genmab; Icahn School of Medicine at Mount Sinai; Medarex; NYU Langone Health; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections; Liver cancer; Non-small cell lung cancer; Squamous cell cancer
- Phase I/II Prostate cancer; Solid tumours
- Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis
Most Recent Events
- 01 Jul 2022 National Cancer Institute plans a phase I/II trial for Myelodysplastic syndromes (Monotherapy, Combination therapy) in USA (IV, Infusion) in July 2022 (NCT05148234)
- 03 Jun 2022 Interim efficacy and adverse events data from a phase Ib/II MAGIC-8 trial in prostate cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 07 Dec 2021 Columbia University and Bristol-Myers Squibb terminates a phase-II trials in COVID-2019 infections in cancer patients (Treatment-experienced) in USA (IV) (NCT04347226)